Febuxotid vk 40 An Thien treats chronic hyperuricemia (3 blisters x 10 tablets)

Dosage form Box of 3 blisters x 10 tablets
Specifications Febuxostat

Ingredient

Composition information	Content
Febuxostat	40mg

Uses

indications

Febuxotid vk drug is indicated for treatment of chronic hyperuricemia in patients with gout.

Febuxostat is not recommended for the treatment of asymptomatic hyperuricemia.

Pharmacokic

Uric acid is the final product of the human metabolism and is created in the hypoxanthin reaction chain ⇒ xanthin ⇒ uric acid. Febuxostat is a 2-anlthiazol derivative, which reduces serum uric acid by inhibiting the Xanthin oxidase enzyme selection (XO).

Dynamic pharmacokinetics

Febuxostat are absorbed quickly and well (at least 84%). The snow -use of the form of Febuxostat tablets has not been studied. The ratio of cohesion to plasma protein is about 99.2% (mainly with albumin).

Febuxostat is widely metabolized through UDPGT enzyme system and oxidation through the Cytochrom P450 system. Febuxostat is removed by both liver and kidney. About 49% of the dose is released in urine and about 45% of the dose is found in stool.

Before taking Febuxotid vk 40 An Thien treats chronic hyperuricemia (3 blisters x 10 tablets)

How to use

Take it once a day, use with food or not.

Dosage

Treatment of chronic hyperuricemia in patients gout:

Adults (18 years or older):

Febuxostat recommended dose is 80 mg once a day. If after 2-4 weeks of treatment, serum uric acid is still higher than 6 mg/dl (357 µmol/l), may consider using Febuxostat 120 mg once a day.

Febuxostat has a quick impact, allowing the concentration of uric acid in serum after only 2 weeks. The goal of treatment is to reduce and maintain serum uric acid levels below 6 mg/dl (357 µmol/l), prevent gout from outbreaks for at least 6 months.

Old people:

No dose adjustment for the elderly.

kidney failure:

Efficiency and safety have not been fully evaluated in patients with severe renal impairment (creatinine clearance

Hepatic failure:

The efficiency and safety of Febuxostat has not been studied in patients with severe liver failure (Child Pugh C). The recommended dose in patients with mild liver failure is 80 mg. Research data is limited in medium liver failure patients.

Children:

Safety and effectiveness of Febuxostat in children aged under 18 have not been determined.

Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What to do when overdose? However, the recommended overdose should not be used. Patients should be treated for symptoms and support treatment if an overdose occurs.

What to do when you forget 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double dose to compensate for missed dose.

Side Effects

When using Febuxotid vk, you may experience unwanted effects (ADR).

Common, ADR> 1/100

Neurological: headache

Endocrine, metabolism: Gout level

digestive: diarrhea, nausea

Liver: Liver function abnormalities

Skin and subcutaneous tissue: rash

Systemic: Fatigue

Uncommon, rare, ADR

Hematology: reduces 3 lines of blood cells, reduces platelets.

immune: Anaphylaxis, hypersensitivity.

Endocrine, metabolism: increased hormonal stimulating thyroid in blood, diabetes, hyperlipidemia.

Cardiovascular: Atrial fibrillation, chest drum, abnormal electrocardiogram, hypertension, flushing.

Respiratory: Difficulty breathing, bronchitis, upper respiratory infection, cough.

digestive: abdominal pain, bloating, dry mouth, indigestion, constipation.

Liver: gallstones.

Skin and subcutaneous tissue: dermatitis, urticaria, itching, skin pigmentation, poisoning epidermal necrosis, Stevens - Johnson syndrome.

musculoskeletal: muscle pain, joint pain, arthritis, muscle pepper.

kidney: kidney failure, kidney stones, bleeding, interstitial nephritis.

Mental: Increasing appetite, weight gain, loss of loss, weight loss, reduction of libido, insomnia, anxiety. nerve: dizziness, paresthesia, hemiplegia, sleeping, changing taste, reducing sensation, reducing smell. vision: blurred vision.

ear and vestibular system: Tinnitus.

Systemic: edema, chest pain, chest tightness.

Instructions on how to handle ADR

Stop medication and contact the doctor immediately or go to the nearest emergency room if allergic reactions occur:

Anaphylaxis reactions, allergies.

Warnings

Before using the drug you need to read the instructions carefully and refer to the information below.

Contraindicated

Febuxotid VK is contraindicated in the following case: Patients treated with azathioprin or mercaptopurin.

Caution when using

should not use Febuxostat in patients with anemia or congestive heart failure.

Serious di/hypersensitivity reactions, including Stevens - Johnson syndrome, threatened life, poisoned epidermis and acute anaphylactic/shocking reactions were reported when treated with Febuxostat.

Patients must be notified of signs and symptoms, closely monitor the symptoms of allergic/hypersensitivity reactions. Febuxostat should be stopped immediately if there are serious reactions, including Stevens - Johnson syndrome.

If allergic/hypersensitivity reactions include Stevens - Johnson syndrome and acute/shocking anaphylactic reaction, not to start again in this patient group.The acute gout can occur at the beginning of treatment due to changes in serum uric acid levels leading to the release of urate crystals at tissue. Recommendation when starting with Febuxostat, should be used with NSAID or Colchicin for at least 6 months. If acute gout occurs during Febuxostat treatment, do not stop the drug.

Patients with the risk of increased urate formation (for example, malignant diseases and treatment of malignant diseases, Lesch - Nyhan syndrome), the absolute concentration of xanthin in the urine may increase enough to accumulate in urinary tract in some rare cases.

Febuxostat is not recommended for patients treated simultaneously with mercaptopurine/azathioprin.

Patients with organ transplants should not be used because there is no enough data to conclude.

Mild liver failure has been observed in patients treated with Febuxostat. Liver function tests are proposed before starting treatment and periodically based on clinical evaluation.

Be careful when using Febuxostat in patients with changes in the thyroid function due to the increase in TSH value (> 5.5 µu/ml) observed in long -term patients with Febuxostat.

The ability to drive and operate machinery

The drug can cause dizziness, drowsiness, blurred vision, numbness or tingling feeling during treatment. So do not drive or operate machinery if affected.

Pregnancy

data on a very limited number of unwanted pregnancy cases has not shown any febuxostat side effects on pregnancy or health of fetus/infant.

Animal research does not show direct or indirect harm to pregnancy, the development of fetus/embryos. The potential risks to humans are unknown. Febuxostat should not be used during pregnancy.

Breastfeeding period

There is no data on Febuxostat's output into breast milk. Animal studies have shown the elimination of this active ingredient in breast milk and decreased the growth of the child. Risks for breastfed babies can not be excluded. Febuxostat should not be used when breastfeeding.

Drug interaction

mercaptopurine/azathioprin: febuxostat can cause increased plasma concentration of these drugs leading to poisoning.

Glucuronid chemical process: The drug that causes strong enzyme enzyme can lead to increased febuxostat metabolism and reduce the effectiveness of the drug. Therefore, the serum uric acid should be monitored for 1-2 weeks after starting treatment with glucuronide touch. In contrast, stop treatment with touch substance can lead to increased concentration of febuxostat.

Storage

Store in a dry place, the temperature does not exceed 30 ° C, avoiding light.

Other drugs

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.